Results 61 to 70 of about 1,082,719 (367)

Neural connectivity predicts spreading of alpha-synuclein pathology in fibril-injected mouse models: Involvement of retrograde and anterograde axonal propagation. [PDF]

, 2020
In Parkinson's disease, some of the first alpha-synuclein aggregates appear in the olfactory system and the dorsal motor nucleus of the vagus nerve before spreading to connected brain regions.
Brundin, Patrik, Mezias, Christopher, Raj, Ashish, Rey, Nolwen   +3 more
core   +2 more sources

Sociodemographic Characteristics and Comorbidities of Patients With Long COVID and Persistent Olfactory Dysfunction

JAMA Network Open, 2022
Key Points Question What are the sociodemographic and clinical characteristics of patients with long COVID and persistent olfactory dysfunction? Findings In this cross-sectional study of 219 patients with long COVID and neurologic symptoms, 64% had ...
Alna Carolina Mendes Paranhos, Ápio Ricardo Nazareth Dias, Livia Caroline Machado da Silva, Gisele Vieira Hennemann Koury, Emanuel de Jesus Sousa, Antônio José Cerasi, G. Souza, Juarez Antônio Simões Quaresma, Luiz Fábio Magno Falcão   +8 more
semanticscholar   +1 more source

Drug-induced Parkinson's disease modulates protein kinase A and Olfactory Marker Protein in the mouse olfactory bulb [PDF]

, 2017
Background Olfaction is often affected in parkinsonian patients, but dopaminergic cells in the olfactory bulb are not affected by some Parkinson-inducing drugs.
Caretta, Antonio, Mucignat, Carla
core   +2 more sources

COVID-19 and olfactory dysfunction: a looming wave of dementia?

Journal of Neurophysiology, 2022
Olfactory dysfunction is a hallmark symptom of COVID-19 disease resulting from the SARS-CoV-2 virus. The cause of the sudden and usually temporary anosmia that most people suffer from COVID-19 is likely entirely peripheral - inflammation and other damage
L. Kay
semanticscholar   +1 more source

Disease-specific, neurosphere-derived cells as models for brain disorders [PDF]

, 2010
There is a pressing need for patient-derived cell models of brain diseases that are relevant and robust enough to produce the large quantities of cells required for molecular and functional analyses.
Abrahamsen, G., An, J., Anderson, M., Beckhouse, A.G., Bellette, B., Bennebroek, M., Cecil, R., Chalk, A.M., Cochrane, J., Cook, A.L., Fan, Y., Féron, F., Mackay-Sim, A., Mahler, S., Matigian, N., McCurdy, R., McGrath, J.J., Mellick, G.D., Murrell, W., Nouwens, A., Perry, C., Raju, J., Ravishankar, S., Silburn, P.A., Sue, C.M., Sutharsan, R., Sutherland, G.T., Vitale, A.M., Wells, C.A., Wood, S.A.   +29 more
core   +1 more source

Therapies for Olfactory Dysfunction — an Update

Current Allergy and Asthma Reports, 2022
Olfactory dysfunction is a prevalent condition affecting 5–15% of the general population, with significant impact on quality of life. This review summarizes the most recent and relevant literature in the treatment of olfactory dysfunction.
A. Jafari, E. Holbrook
semanticscholar   +1 more source

Olfactory Evaluation in Alzheimer’s Disease Model Mice

Brain Sciences, 2022
Olfactory dysfunction is considered a pre-cognitive biomarker of Alzheimer’s disease (AD). Because the olfactory system is highly conserved across species, mouse models corresponding to various AD etiologies have been bred and used in numerous studies on
Jingjing Zhang, Zixuan Zhao, Siqi Sun, Jing Li, Yu Wang, Jingyin Dong, Su Yang, Yiyi Lou, Jing Yang, Weiyun Li, Shanshan Li   +10 more
doaj   +1 more source

The use of platelet-rich plasma in treatment of olfactory dysfunction: A pilot study. [PDF]

, 2020
BackgroundOlfactory dysfunction is a prevalent problem with a significant impact on quality of life and increased mortality. Limited effective therapies exist.
Mundy, David C, Patel, Zara M, Yan, Carol H   +2 more
core   +1 more source

Olfactory Dysfunction in Patients With Mild COVID-19 During Gamma, Delta, and Omicron Waves in Rio de Janeiro, Brazil.

Journal of the American Medical Association (JAMA), 2022
OlfactorydysfunctionisacommonsymptomofCOVID-19,with reportedratesashighas70%.Thissymptomcanbeassociated with mild COVID-19, mostly occurs within 5 days after symp-tomonset,andcanpersistforafewdaystoseveralmonthsafter infection resolution. 1 The mechanism
C. C. Cardoso, Á. D. Rossi, R. Galliez, D. Faffe, A. Tanuri, T. Castiñeiras   +5 more
semanticscholar   +1 more source

Corticosteroids for COVID-19-induced olfactory dysfunction: A comprehensive systematic review and meta-analysis of randomized controlled trials.

PLoS ONE, 2023
BackgroundOlfactory dysfunction is a common manifestation in COVID-19 patients and can significantly impact their quality of life. Corticosteroids have been proposed as a potential treatment, but their efficacy remains controversial.
Jian-Ying Wang, Jiunn-Bey Pao, Chih-Hsin Lee, Jann-Yuan Wang, Ming-Chia Lee, Tzu-Tuan Wu   +5 more
doaj   +1 more source